메뉴 건너뛰기
New England Journal of Medicine
Volumn 363, Issue 8, 2010, Pages 779-781
Treating cancer by targeting the immune system
Author keywords

[No Author keywords available]
Indexed keywords

CD20 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; IPILIMUMAB; RITUXIMAB; TRASTUZUMAB;
EID: 77955874663     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1006416     Document Type: Editorial
Times cited : (41)
References (10)
  • 1
    • 0035056017 scopus 로고    scopus 로고
    • CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
    • Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
    • (2001) Annu Rev Immunol , vol.19 , pp. 565-594
    • Chambers, C.A.1    Kuhns, M.S.2    Egen, J.G.3    Allison, J.P.4
  • 2
    • 0028791059 scopus 로고
    • Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
    • Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-8.
    • (1995) Science , vol.270 , pp. 985-988
    • Waterhouse, P.1    Penninger, J.M.2    Timms, E.3
  • 3
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 4
    • 24944459890 scopus 로고    scopus 로고
    • Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    • Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
    • (2005) J Clin Oncol , vol.23 , pp. 6043-6053
    • Attia, P.1    Phan, G.Q.2    Maker, A.V.3
  • 5
    • 70350135349 scopus 로고    scopus 로고
    • A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
    • abstract
    • Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009;27:Suppl:18s. abstract.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Schwartzentruber, D.J.1    Lawson, D.2    Richards, J.3
  • 6
    • 77955892831 scopus 로고    scopus 로고
    • Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma
    • abstract
    • Prieto PA, Yang JC, Sherry RM, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: long-term follow-up of 179 patients with metastatic melanoma. J Clin Oncol 2010;28:Suppl:15s. abstract.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Prieto, P.A.1    Yang, J.C.2    Sherry, R.M.3
  • 7
    • 65249173447 scopus 로고    scopus 로고
    • Adoptive cell therapy for the treatment of patients with metastatic melanoma
    • Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-40.
    • (2009) Curr Opin Immunol , vol.21 , pp. 233-240
    • Rosenberg, S.A.1    Dudley, M.E.2
  • 8
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
    • (2009) Clin Cancer Res , vol.15 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3
  • 9
    • 67651246671 scopus 로고    scopus 로고
    • Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer
    • abstract
    • Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27:Suppl:461s. abstract.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Flaherty, K.1    Puzanov, I.2    Sosman, J.3
  • 10
    • 77955917121 scopus 로고    scopus 로고
    • Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
    • abstract. Accessed July 28, 2010, at
    • Sznol M, Powderly JD, Smith DC, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010;28:Suppl. abstract. (Accessed July 28, 2010, at http://meeting.ascopubs.org/cgi/content/abstract/28/15-suppl/2506.)
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Sznol, M.1    Powderly, J.D.2    Smith, D.C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.